Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medicus Pharma Ltd. (NASDAQ: MDCX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including registration statements, current reports and financing-related documents. Medicus is an Ontario-incorporated biotech and life sciences company focused on SkinJect™, a doxorubicin microneedle array for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for prostate and urologic indications.
Key filing types for MDCX include registration statements on Form S-1, which describe offerings and resale registrations tied to standby equity purchase agreements, warrant exercises and acquisition-related consideration shares. These S-1 filings outline the company’s business, risk factors, pipeline programs and capital structure in detail. Investors can review sections covering the SkinJect™ and Teverelix clinical programs, as well as the terms of equity facilities with counterparties such as YA II PN, Ltd. (Yorkville) and Armistice Capital Master Fund Ltd.
Current reports on Form 8-K document material events such as the acquisition of Antev Limited, warrant inducement agreements, new debenture financings, non-binding memoranda of understanding, and updates on clinical and regulatory milestones. For example, 8-K filings describe the Antev transaction that added Teverelix to the pipeline, the terms of a debenture issued to Yorkville, and inducement arrangements for the exercise of outstanding warrants.
Through this page, users can also monitor unregistered sales of equity securities disclosed under Item 3.02 of Form 8-K, which provide insight into how Medicus funds its clinical development activities. While insider Form 4 reports are not summarized in the provided data, Stock Titan’s platform is designed to surface such ownership changes when available.
How Stock Titan helps
Stock Titan enhances these filings with AI-powered summaries that explain complex documents in plain language, highlight key terms in S-1 and 8-K filings, and point out items relevant to Medicus’s SkinJect™ and Teverelix programs. Real-time EDGAR updates mean new MDCX filings appear quickly, and investors can use this page to track registration statements, financing terms and other regulatory disclosures without reading every page of each filing.
Medicus Pharma, Inc. (MDCX) filed an S-1 registration including a prospectus structure and partial financial schedules. The filing shows multiple equity issuances during 2024–2025: common shares and warrants were issued under a Regulation A offering with issuance costs of $483,020, and a later equity financing with net offering costs of $809,606. The company records repeated net loss and comprehensive loss for successive periods and reports stock-based compensation expense and share issuances upon warrant exercises. Financing activities include proceeds from common shares and warrants, debentures and convertible notes, with related issuance costs and non-cash adjustments. The cash flow section lists net cash used in operating activities and net cash provided by financing activities, and the balance sheet excerpts reference money market funds and debentures measured at fair value. The filing also discloses operating lease right-of-use assets and liabilities, valuation inputs for warrants/options, and certain redactions under Regulation S-K.
Medicus Pharma Ltd. filed an offering circular supplement dated September 18, 2025 registering 1,490,000 common shares issuable upon the exercise of outstanding warrants.
Concurrently, the company entered into a securities purchase agreement with YA II PN, Ltd. (Yorkville) for a $8,000,000 debenture. Net proceeds were approximately $5.7 million after satisfaction of an existing $1.7 million debt balance and fees. The Debenture bears interest at 8.00% per annum (increasing to 18.00% upon certain defaults), matures on September 17, 2026, and requires monthly repayments of $650,000 plus accrued interest beginning 45 days after issuance. Each subsidiary entered into a global guaranty in favor of Yorkville.
Medicus Pharma Ltd. entered into a new financing deal with YA II PN, Ltd. (Yorkville), issuing a debenture with a principal amount of $8,000,000. The company received approximately $5.7 million in net proceeds after using about $1.7 million to fully repay remaining debentures from a May 2025 financing and accounting for original issue discount and fees. The debenture carries 8.00% annual interest, which can increase to 18.00% if certain events of default occur, and matures on September 17, 2026. Medicus must make monthly payments of $650,000 plus accrued interest in cash starting 45 days after issuance, with any remaining balance due at maturity. All company subsidiaries entered into a global guaranty in favor of Yorkville, and the company may redeem the debenture early in cash, in whole or in part.
Medicus Pharma Ltd. filed an offering circular supplement covering 1,490,000 common shares issuable upon the exercise of its warrants. These public warrants have a $4.64 exercise price and expire on November 15, 2029, and trade on Nasdaq under the symbol MDCXW, while the common shares trade as MDCX.
The supplement attaches a current report describing leadership changes. Chief Financial Officer James Quinlan began a medical leave of absence on September 12, 2025, and President Carolyn Bonner was appointed Acting CFO without additional compensation. On September 11, 2025, the common shares and public warrants last traded at $2.41 and $0.76, respectively.
Patrick J. Mahaffy, a director of Medicus Pharma Ltd. (MDCX), reports beneficial ownership of 35,435 common shares and a stock option for 25,000 common shares exercisable through 08/29/2030 at an exercise price of $1.94. The option vests in equal quarterly installments over the 12 months following 08/29/2025. The Form 3 was signed by an attorney-in-fact on 09/08/2025.
Medicus Pharma Ltd. is offering 1,490,000 common shares issuable upon the exercise of its Nasdaq-listed public warrants, and this supplement updates that ongoing Regulation A offering with information from a recent current report.
Medicus completed its acquisition of 98.6% of Antev Ltd., paying approximately US$3.0 million in cash plus 1,603,164 Medicus common shares, with up to about $65 million in additional milestone-based contingent consideration tied to future FDA Phase 2 and New Drug Application outcomes for Teverelix. The company also sold an aggregate 250,000 common shares to Yorkville for roughly $490,535 under a standby equity purchase agreement and plans to use part of the proceeds to prepay outstanding debentures with Yorkville. In connection with the transaction, former Antev chairman Patrick J. Mahaffy joined the Medicus board, receiving cash board fees and 25,000 stock options vesting over one year.
Medicus Pharma Ltd. has completed its previously announced acquisition of 98.6% of Antev Ltd., a clinical-stage biotech developing Teverelix for high-risk prostate cancer and acute urinary retention. The deal consideration includes approximately US$3.0 million in cash and 1,603,164 Medicus common shares, with Antev vendors potentially earning up to $65 million in future milestone-based contingent payments tied to FDA Phase 2 and New Drug Application approvals.
The Consideration Shares were issued in a private, unregistered placement and are subject to staggered lock-up releases over roughly seven months after a resale registration statement becomes effective, with any remaining shares released by the nine-month anniversary of closing. Medicus also raised about $490,535 via Standby Equity Purchase Agreement advances by selling an aggregate 250,000 common shares to Yorkville and plans to use part of the proceeds to prepay debentures. In connection with the transaction, former Antev chairman Patrick J. Mahaffy joined Medicus’s board and received 25,000 stock options with a five-year term and a $1.94 exercise price.
Medicus Pharma Ltd. filed an offering circular supplement covering 1,490,000 common shares issuable upon exercise of its public warrants. The public warrants have a $4.64 exercise price, expire on November 15, 2029, and trade on Nasdaq under the symbol MDCXW, while the common shares trade as MDCX; on August 21, 2025, they closed at $2.45 and $0.93, respectively.
The attached report also discloses unregistered sales of 809,654 common shares to Yorkville under a Standby Equity Purchase Agreement, for approximate aggregate consideration of $1,651,464. Medicus plans to use part of the net proceeds to prepay a portion of debentures held by Yorkville. In addition, the chief financial officer exercised stock options for 145,000 common shares for cash, providing the company with approximately $156,250 in proceeds.
Medicus Pharma Ltd. reported recent unregistered equity sales and an insider option exercise. Under its Standby Equity Purchase Agreement with Yorkville, the company sold a total of 809,654 common shares between July 30 and August 21, 2025 for approximate aggregate consideration of $1,651,464. The company plans to use part of the net proceeds to prepay a portion of debentures outstanding with Yorkville.
In addition, on August 13, 2025, the Chief Financial Officer exercised stock options for 145,000 common shares, providing the company with aggregate cash proceeds of about $156,250. The company also noted a press release describing updates on its proposed Type C Meeting with the FDA and its second quarter 2025 financial highlights.
Schedule 13G amendment filed by Armistice Capital, LLC and Steven Boyd discloses a shared beneficial ownership of 935,724 common shares of Medicus Pharma Ltd., representing 4.99% of the class. The filing states Armistice Capital acts as investment manager to Armistice Capital Master Fund Ltd., the direct holder, and that Mr. Boyd, as managing member, may be deemed to beneficially own the shares. Voting and dispositive power are reported as shared (935,724 shares) with no sole voting or dispositive power.